FKONCO

DSP Merrill Lynch Limited has submitted to the Exchange a copy of Exit offer Public Announcement made by Fresenius Kabi (Singapore) Pte Ltd to the public shareholders of Fresenius Kabi Oncology Limited ("company") ("Delisting Offer").

Fresenius Kabi Oncology Limited has, with reference to the Delisting of the equity shares of the Company from the Exchange, submitted to the Exchange the details of the name, address and contact numbers of the Contact Person at RTA and at the Company for solving Investor queries post Delisting.

Members of the Exchange are hereby informed that the trading in the equity shares of Fresenius Kabi Oncology Limited shall be suspended w.e.f. January 03, 2014 (i.e. w.e.f. closing hours of trading on January 02, 2014 ) on account of voluntary delisting pursuant to the SEBI (Delisting of Equity Shares) Regulations, 2009. The admission to dealings in securities of the said company shall be withdrawn (delisted) w.e.f. January 10, 2014. Further, It may be noted that SEBI has informed the Exchange vide its letter dated December 20, 2013 that they have filed an appeal in this matter in the Hon ble

Fresenius Kabi Oncology Limited has informed the Exchange that Dr. Patricia Grigoleit , Non-Executive Director of the Company, has resigned from the directorship of the Company with effect from December 11, 2013.

DSP Merrill Lynch Limited has submitted to the Exchange a copy Post offer Public Announcement ("Post Offer PA") is being issued by Fresenius Kabi (Singapore) Pte Ltd ("Acquirer") to the Public Shareholders of the Fresenius Kabi Oncology Limited ("Company"). This Post Offer PA is in continuation of and should be read in conjunction with, (i) the public announcement published on September 16, 2013 ( PA ) in respect of the proposed acquisition by the Acquirer and consequent delisting of the fully paid-up equity shares of the Company with a face value of Re. 1 each ("Shares") from the BSE Limited

Fresenius Kabi Oncology Limited has submitted to the exchange the standalone financial results for the period ended 30-sep-2013.

DSP Merrill Lynch Limited has submitted to the Exchange a copy of the Supplement to the Second Corrigendum ("Corrigendum") to the Public Announcement issued pertaining to the delisting offer made by Fresenius Kabi (Singapore) Pte Ltd to the public shareholders of Fresenius Kabi Oncology Limited ("Company") ("Delisting Offer").

Fresenius Kabi Oncology Limited has informed the Exchange that with reference to the earlier letter dated October 18, 2013, informing about the Securities Appellate Tribunal's (SAT) order dated October 18, 2013, granting the Company an extension of 2 months from October 22, 2013 for completing the Delisting Offer, Fresenius Kabi Oncology Ltd has now informed that the Company has on October 21, 2013 has received the copy of aforementioned SAT order dated October 18, 2013.

DSP Merrill Lynch Limited has informed the Exchange regarding the Second Corrigendum ("Corrigendum") to the Public Announcement issued pertaining to the delisting offer made by Fresenius Kabi (Singapore) Pte Ltd to the public shareholders of Fresenius Kabi Oncology Limited ("Company") ("Delisting Offer").

Fresenius Kabi Oncology Limited had informed the Exchange regarding the delisting update dated October 14, 2013. The Company has now informed the Exchange that the Company had filed a Miscellaneous Application No. 113 of 2013 in Appeal No. 133 of 2013 before the Hon'ble Securities Appellate Tribunal (SAT) seeking an extension of time to complete the Delisting Offer. The Hon'ble SAT disposed off the SAT Application on October 18, 2013. An order was passed in the open court granting the Company an extension of 2 months from October 22, 2013 for completing the Delisting Offer.

Fresenius Kabi Oncology Limited had informed the Exchange regarding the delisting update dated October 12, 2013. The Company has now informed that Securities and Exchange Board of India (SEBI), vide its letter dated October 14, 2013, has advised the Company to approach Securities Appellate Tribunal (SAT) for seeking any relief including extension of time.

DSP Merrill Lynch Limited has informed the Exchange regarding Corrigendum ("Corrigendum") to the Public Announcement issued pertaining to the delisting offer made by Fresenius Kabi (Singapore) Pte Ltd to the public shareholders of Fresenius Kabi Oncology Limited ("company") ("Delisting Offer").

Fresenius Kabi Oncology Limited has informed the Exchange that the promoter of the Company i.e. Fresenius Kabi (Singapore) Pte Ltd. ("FKSL ) has informed that in terms of paragraph 20.1 of the public announcement dated September 16, 2013 ("PA ) and the corresponding letters of offer ("Letter of Offer ) despatched to the public shareholders of the Company, the acquisition of shares of the Company by FKSL pursuant to the delisting offer is subject to the decision of the Securities and Exchange Board of India ( SEBI ) on the application dated September 12, 2013 filed by the Company seeking an ext

Fresenius Kabi Oncology Limited has informed the Exchange that Mr. Rajiv Lochan Jain has been appointed as an Additional Director of the Company w.e.f. October 03, 2013 under "Independent Category" via Board of Directors Resolution passed by circulation on October 07, 2013.

DSP Merrill Lynch Limited has submitted to the Exchange a copy of public announcement ("Public Announcement") issued by Fresenius Kabi (Singapore) Pte Ltd. ("Acquirer") to the public shareholders of Fresenius Kabi Oncology Limited ("Company") in respect of the proposed acquisition and consequent delisting of the fully paid-up equity shares of the Company from the BSE Limited ( BSE ) and the National Stock Exchange of India Limited ( NSE ) in accordance with the Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2009 ("Delisting Regulations"). The Acquirer is the p

Fresenius Kabi Oncology Limited has informed the Exchange that Hon'ble Securities Appellate Tribunal, Mumbai (SAT), vide its order dated September 10, 2013, has allowed the appeal filled by the Company against order dated July 22, 2013 passed by the Securities and Exchange Board of India (SEBI) to extent that the Company may go ahead with the delisting offer without the condition imposed by Securities and Exchange Board of India (SEBI) regarding compliance with Regulation 17(b) of SEBI (Delisting of Equity Shares) Regulations, 2009.

Fresenius Kabi Oncology Limited has informed the Exchange that "Mr. Thomas Georg Mechtersheimer, Non Executive Director of the Company, has sent his resignation from the directorship of the Company with effect from August 31, 2013".

Fresenius Kabi Oncology Limited has informed the Exchange regarding the outcome of the Annual General Meeting of the Company held on August 08, 2013.

Fresenius Kabi Oncology Limited has informed the Exchange that with reference to the earlier announcement dated February 26, 2013 regarding US FDA inspection resulting in putting on hold the production at Company's API plant located at Kalyani, District Nadia, West Bengal, (India) and subsequent warning letter dated July 01, 2013, asking for certain other information and implementation of more corrective and preventive measures so as to avoid recurrence of deviations. In view of the observation made by US FDA, the Company had initiated necessary corrective and preventive steps for improving qu

Fresenius Kabi Oncology Limited has informed the Exchange vide letter dated August 08, 2013 regarding the voting results at the Annual General Meeting of the Company held on August 08, 2013 under clause 35A of the Listing Agreement.

Fresenius Kabi Oncology Limited has submitted to the Exchange the Standalone Financial Results along with the Limited Review Report for the period ended June 30,2013.

Fresenius Kabi Oncology Limited has informed the Exchange that the Company had filed an appeal (no. 133 of 2013) before Hon'ble Securities Appellate Tribunal, Mumbai (SAT) against the directions contained in paragraph 13(ii) of order no. WTM/PS/16/CFD/JULY/2013, dated July 22, 2013 passed by the Securities and Exchange Board of India (SEBI). In this regard, the Company has submitted to the Exchange a copy of the SAT order dated August 01, 2013.

Fresenius Kabi Oncology Limited has informed the Exchange that Mr. Rajiv Lochan Jain has been appointed as an Additional Director of the Company w.e.f. August 06, 2013 under "Independent Category".

Fresenius Kabi Oncology Limited has informed the Exchange that on July 22, 2013 Hon'ble Whole Time Member of the Securities and Exchange Board of India ("SEBI") passed an order, allowing the Company to continue with the delisting offer/process subject to certain terms and conditions as mentioned in the said order. Further, as per this order, the Company has been, inter alia, instructed to complete the delisting process within three months from the date of the order.

Fresenius Kabi Oncology Limited has informed the Exchange that the Register of Members and Share Transfer Books of the Company will remain closed from July 29, 2013 to August 08, 2013 (both days Inclusive) for the purpose of Annual General Meeting of the Company scheduled to be held on August 08, 2013.

Fresenius Kabi Oncology Limited has informed the Exchange that with reference to the earlier announcement dated February 26, 2013, regarding putting on hold the production at Company's API plant located at Kalyani, District Nadia, West Bengal, (India) in view of certain observations made by US FDA in respect of manufacturing, documentation practices and product testing during a routine inspection. The Company has now informed the Exchange that the Company has received a warning letter from US FDA, inter-alia, asking for certain other information and implementation of more corrective and preven

Fresenius Kabi Oncology Limited has informed the Exchange that: "On June 04, 2013, the Hon'ble Whole Time Member of the Securities and Exchange Board of India ("SEBI") passed an interim order (Ref no: WTM/PS/08/CFD/JUNE/2013) ("Order") - (a) directing the freezing of voting rights and corporate benefits with respect to the excess of proportionate promoter shareholding in the Company, till such time that the Company complies with the minimum public shareholding ("MPS") norms; (b) prohibiting the promoter of the Company and directors of the Company from buying, selling or otherwise dealing in se

Fresenius Kabi Oncology Limited has submitted to the Exchange a copy of an abstract of the terms and condition regarding re-appointment of Mr. Peter F. Nilsson as the Managing Director & CEO of the Company for a further period of two year i.e. from October 20, 2013 to October 19, 2015.

Fresenius Kabi Oncology Limited has informed the Exchange that Mr. Nitin Potdar, Independent Director, has resigned from the directorship of the Company with immediate effect.

Fresenius Kabi Oncology Limited has informed the Exchange that "In continuation to our earlier letter, dated April 17, 2013, please be informed that the Company has obtained requisite shareholders' approval through Postal Ballot on the Special Resolution for delisting of the equity shares of the Company from the stock exchanges in accordance with the SEBI (Delisting of Equity Shares) Regulations, 2009, as specified in the notice of Postal Ballot dated April 17, 2013, read with explanatory statement attached thereto".

Fresenius Kabi Oncology Limited has informed the Exchange regarding the Outcome of Board Meeting of the Company held on May 27, 2013.

Fresenius Kabi Oncology Limited has submitted to the Exchange the Standalone Financial Results for the period ended March 31,2013.

Fresenius Kabi Oncology Limited has submitted to the Exchange vide letter dated April 23, 2013 a copy of notice of Postal Ballot pursuant to Section 192A(2) of the Companies Act, 1956 read with the Companies (Passing of the Resolution by Postal Ballot) Rules, 2011 together with Explanatory Statement of the Postal Ballot being conducted by the Company to transact the following business: (1) Special Resolution regarding voluntarily delisting of the equity shares of the Company from the stock exchanges in accordance with the SEBI (Delisting of Equity Shares) Regulations, 2009.

Fresenius Kabi Oncology Limited has informed the Exchange that "With reference to earlier announcement dated April 17, 2013, the Company has received a letter dated April 16, 2013 ("Letter") from Fresenius Kabi (Singapore) Pte Ltd, the promoter shareholder of the Company ("FKSL") notifying the Company of its intention to make a voluntary delisting offer to the public shareholders of the Company ("Delisting Offer") to acquire the entire public shareholding of the Company (i.e. 3,00,63,255 equity shares of Re. 1 each, representing 19% of the share capital of the Company) and delist the equity sh

Fresenius Kabi Oncology Limited has informed the Exchange that the Company has received a letter dated April 16, 2013 ("Letter") from its promoter shareholder, Fresenius Kabi (Singapore) Pte Ltd. ("FKSL") notifying the Company of its intention to make a voluntary delisting offer to the public shareholders of the Company to acquire the entire public shareholding of the Company (i.e. 30,063,255 equity shares of Re. 1 each, representing 19% of the share capital of the Company) and delist the equity shares of the Company from the stock exchanges on which the equity shares of the Company are presen

Fresenius Kabi Oncology Limited has informed the Exchange that during a recent routine US FDA inspection at Company's API plant located at Kalyani, District Nadia, West Bengal, (India), US FDA made certain observations relating to GMP non-conformities in respect of manufacturing, documentation practices and product testing. However, all finished products conform to approved standards and specifications. The Company has immediately taken steps to implement remedial measures and has voluntarily put the production on hold. The Company's dosage form plants in Himachal Pradesh continue normal produ

Fresenius Kabi Oncology Limited has informed the Exchange that the Board of Directors of the Company at their meeting held on February 13, 2013 the Board interalia, approved/took note of the following: (1) Appointment of Dr. Patricia Grigoleit as an Additional Director of the Company w.e.f. February 13, 2013; (2) Appointment of Dr. Satish B. Kulkarni as an Alternate Director in place of Mr. Thomas George Mechtersheimer. This appointment was effective for the Board Meeting dated February 13, 2013 and Dr. Kulkarni resigned from the Alternate Directorship at the conclusion of the meeting.

Fresenius Kabi Oncology Limited has submitted to the Exchange the Standalone Financial Results along with the Limited Review Report for the period ended December 31, 2012.

Fresenius Kabi Oncology Limited has submitted to the Exchange the Standalone Financial Results along with the Limited Review Report for the period ended September 30,2012.

Fresenius Kabi Oncology Limited has submitted to the Exchange vide letter dated October 16, 2012 a copy Disclosure under regulation 13(6) of the SEBI (Prohibition of Insider Trading Regulations), 1992.

Fresenius Kabi (Singapore) Pte Ltd has submitted to the Exchange vide letter dated October 15, 2012 a copy of Disclosure in terms of Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 along with Regulation 13(3), 13(4), 13(4A) & 13(6) and of SEBI (Prohibition of Insider Trading) Regulations, 1992.

Fresenius Kabi (Singapore) Pte Ltd had informed the Exchange regarding Proposed offer for sale of equity shares of face value of Re.1 each of Fresenius Kabi Oncology Limited ('"Company'") by Fresenius Kabi (Singapore) Pte Ltd (the '"Seller'") through the stock exchange mechanism. The Company has now informed the Exchange the 'Floor Price' for the Sale Shares shall be Rs.80 (Rupees eighty) per equity share.

Fresenius Kabi (Singapore) Pte Ltd has submitted to the Exchange Announcement with respect to Offer for sale through Stock Exchange Mechanism for sale of 11,867,074 equity shares of Re. 1/- each of Fresenius Kabi Oncology Limited by Fresenius Kabi (Singapore) Pte Ltd (Seller) with an option to sell an additional 2,373,415 equity shares of Re. 1/- each. Date and time of the opening of the Offer : October 12, 2012 at 9:15 am and Date and time of the closing of the Offer : October 12, 2012 at 3:30 pm, Floor Price : The floor price shall be intimated on October 11, 2012 after trading hours of the

Fresenius Kabi Oncology Limited has informed the Exchange regarding the Outcome of Annual General Meeting of the Company held on August 09, 2012.

Fresenius Kabi Oncology Limited has informed the Exchange the details regarding the Voting results in the Annual General Meeting of the Company held on August 09, 2012 pursuant to Clause 35A of Listing Agreement.

Fresenius Kabi Oncology Limited has submitted to the Exchange the Standalone Financial Results for the period ended June 30,2012 with Limited Review Report.

Fresenius Kabi Oncology Limited has informed the Exchange that the Board of Directors at their meeting held on May 30, 2012 decided (1) To convene the Annual General Meeting of the Company on August 09, 2012. (2) Fixed the Book Closure period from July 30, 2012 to August 09, 2012 (both days inclusive).

Fresenius Kabi Oncology Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on May 30, 2012, inter alia, has approved / took note of the following: (1) Not recommended any dividend for the financial year 2011-12, (2) Recommended the re-appointment of Dr. Naresh Trehan as a Director liable to retire by rotation, (3) Recommended the re-appointment of Mr. Dilip G. Shah as a Director liable to retire by rotation, (4) Recommended the re-appointment of Mr. Rakesh Bhargava as a Director liable to retire by rotation, (5) Recommended the appointment of Mr. P

Fresenius Kabi Oncology Limited has informed the Exchange that the Company has received a letter dated May 30, 2012 from its promoter shareholder, Fresenius Kabi (Singapore) Pte Ltd. ("FKSL").

Fresenius Kabi Oncology Limited has submitted to the Exchange the Standalone Financial Results for the period ended March 31,2012.